J&J's Medical Devices & Diagnostics Announces Expansion with Innovative Products, Customer-Focused Solutions

At a meeting today withmembers of the investment community, senior leaders from the Medical Devicesand Diagnostics (MD&D) segment of Johnson & Johnson (NYSE: JNJ) will outlineplans to improve patient outcomes and expand their market leadership throughinnovative products, new business models and a significant focus onfast-growing emerging markets.Creating Value through InnovationJohnson & Johnson's MD&D segment is the world's largest medical devices anddiagnostics business, with $28.5 billion in total sales for 2013, driven byten $1 billion-plus platforms that hold the number one or number two positionsin their respective categories. The company's MD&D businesses compete inapproximately 30 percent of the estimated $370 billion global market, and manyof the key markets in which these businesses compete are projected to growfaster than the overall market over the next 5 years.To expand its global leadership position, the MD&D segment invested nearly$1.8 billion in research and development in 2013. The company's MD&Dbusinesses are positioned for continued growth with many recently launchedproducts and a pipeline of more than 30 major product filings planned by theend of 2016. This meaningful innovation is intended to help health caresystems, governments and providers improve clinical outcomes, increase patientsatisfaction and contain costs; three tenets shared by most global health carereform acts, known widely as the Triple Aim."Our businesses are uniquely positioned to continue helping patients whilealso leading the industry by capitalizing on our breadth, depth and scale,"said Dominic J. Caruso, Vice President, Finance and Chief Financial Officerfor Johnson & Johnson. "We are developing innovative products and working withhealth care systems on customer-focused solutions to ultimately improveoutcomes for patients."Global Reach, Local FocusThe medical device segment of emerging markets is growing three-to-four timesfaster than the developed markets, and with almost $6 billion in sales in theMD&D segment coming from these markets – more than 20 percent of its worldwide2013 sales – Johnson & Johnson is leading the industry. Through innovativepartnerships and dedicated strategies to meet the significant unmet needs ofpatients in emerging markets, Johnson & Johnson is well positioned to leadthrough the current evolution health care is experiencing worldwide.In Russia, the company's Vision Care business is piloting new business modelsto engage both eye care professionals and consumers. The acquisition ofSpectrum Vision, which is to be fully integrated this year, dramaticallyincreases the company's market penetration and customer service quality.Today, more than 85 percent of ACUVUE^® Brand Contact Lenses can be deliveredthe same or the next day across all time zones in Russia --  addressing theconsumer's need for speed and convenience.The company's MD&D segment grew at 18 percent* operationally in China in 2013with sales of approximately $1.4 billion, making it the largest of Johnson &Johnson's three business segments in the country. In 2013, the orthopaedicbusiness received approval to manufacture and distribute trauma products fromits plant in Suzhou. As the products launch this year, this local-suppliermodel will give the company access to a new market segment and newreimbursement opportunities.In China, the company's Diabetes Solutions business has a number one marketposition in a country that is home to a quarter of all of the world'sdiabetics. The business has signed an exclusive original equipmentmanufacturer (OEM) agreement with Nova Biomedical Corporation to marketStatStrip^® point-of-care blood glucose testing systems to hospital customersin China - demonstrating its commitment to serving the needs of emergingmarkets."We have a strong business in both developed and emerging markets," said Mr.Caruso. "Building on our 28 year history in China, we are capitalizing on ourestablished footprint to grow and expand our overall business."Excellence in ExecutionDePuy Synthes Companies, the orthopaedics business of the MD&D segment,continues to lead in an attractive and evolving worldwide market. DePuySynthes is realizing revenue and cost synergies from its integration and hasestablished a strong foundation for capturing the full growth potential of thecombined businesses. The business is also today announcing the launch of threenew products: o The GLOBAL^® UNITE^® Anatomic Shoulder System is part of a larger platform enabling surgeons to repair or replace shoulders in a simpler and more efficient manner while optimizing the patient's range of motion. o The CORAIL^® Revision Hip System is the first tapered wedge revision system in the U.S. and is engineered to reduce the operating room footprint while delivering patient benefits through its bone-preserving design. o The TRUMATCH^® Resection Guide for the recently launched ATTUNE^® Rotating Platform Knee. TRUMATCH^® Personalized Solutions provides patient-specific instruments developed from a CT scan to reduce surgical steps and customize the procedure to each patient.The Global Surgery business of Johnson & Johnson is focusing on leveraging itsscale to deliver a pipeline of innovative products that serve large, unmethealth care needs, providing both clinical and economic benefits. The GlobalSurgery business has several key products whose innovation is expected tosignificantly drive growth for the company, including: o HARMONIC ACE^®+ 7 Shears with Advanced Hemostasis – the first purely ultrasonic device with a 7mm vessel sealing indication (Ethicon) o EVARREST™ Fibrin Sealant Patch to stop bleeding (Ethicon) o THERMOCOOL^® SMARTTOUCH™ Contact Force Sensing Catheter for atrial fibrillation (Biosense Webster) o INCRAFT^® Stent Graft System for abdominal aortic aneurysms (AAA) (Cordis)Leading with PurposeThe Johnson & Johnson mission is to care for the world one person at a time.Last year, Johnson & Johnson donated more than $1 billion in products andservices around the world, making life-changing, long-term differences inhuman health. The businesses in the MD&D segment are leading with purposethrough their support of organizations that educate and help patients returnto living healthy, active lives, and through global training centers andinstitutes that are enhancing the standard of care in emerging markets.About Today's MeetingThe meeting will be live-streamed via webcast starting at 9:30 a.m. today andcan be accessed along with the meeting agenda, list of speakers, speaker bios,and full copies of the presentations via the Johnson & Johnson InvestorRelations website www.investor.jnj.com.  A replay and podcast will beavailable approximately two hours after the live webcast. A live Twitter feedfor today's meeting is accessible via #JNJMDD14.